Fondaparinux sodium

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Fondaparinux Sodium 是一种抗凝血酶依赖性 Xa 因子抑制剂，具有抗血栓形成活性。

Fondaparinux sodium is a factor Xa inhibitor to form the high affinity binding site for the anti-coagulant factor antithrombin III (ATIII).(In Vitro):Fondaparinux sodium is the first agent of a new class of anticoagulants that selectively target factor Xa. For Fondaparinux, its IC50 values (anti-Xa IU/ml) are 0.59±0.05 for activated monocytes (ac-M) and 0.17±0.03 for monocyte-derived microparticles (MMPs).(In Vivo):Fondaparinux sodium has a linear, dose-dependent pharmacokinetic profile, which provides a highly predictable response. Fondaparinux sodium is 100% bioavailable, has a rapid onset of action, and has a half-life of 14 to 16 hours, allowing for sustained antithrombotic activity over a 24-hour period. The drug does not affect prothrombin time or activated partial thromboplastin time, nor does it affect platelet function or aggregation.

Fondaparinux sodium is the first agent of a new class of anticoagulants that selectively target factor Xa. For Fondaparinux, its IC50 values (anti-Xa IU/ml) are 0.59±0.05 for activated monocytes (ac-M) and 0.17±0.03 for monocyte-derived microparticles (MMPs).

Fondaparinux sodium has a linear, dose-dependent pharmacokinetic profile, which provides a highly predictable response. Fondaparinux sodium is 100% bioavailable, has a rapid onset of action, and has a half-life of 14 to 16 hours, allowing for sustained antithrombotic activity over a 24-hour period. The drug does not affect prothrombin time or activated partial thromboplastin time, nor does it affect platelet function or aggregation.

Fondaparinux sodium | PENTA | Arixtra

Others

Other Targets

Factor Xa

Cardiovascular Disease

——

114870-03-0

1729.09

C31H44N3Na10O49S8

>98% (HPLC)

H2O : ≥ 30 mg/mL 17.26 mM

[C@H]1([C@H]([C@@H](O[C@@H]2[C@@H](O[C@H]([C@@H]([C@H]2O)OS(=O)(=O)[O-])O[C@H]2[C@@H]([C@H]([C@H](O[C@@H]2COS(=O)(=O)[O-])OC)NS(=O)(=O)[O-])O)C(=O)[O-])O[C@@H]([C@H]1O[C@@H]1O[C@@H]([C@H]([C@@H]([C@H]1O)O)O[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)COS(=O)(=O)[O-])O)O)NS(=O)(=O)[O-])C(=O)[O-])COS(=O)(=O)[O-])NS(=O)(=O)[O-])OS(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]

sodium (2S,3S,4R,5R,6R)-6-(((2R,3R,4R,5R,6R)-6-(((2R,3S,4S,5R,6R)-2-carboxylato-4-hydroxy-6-(((2R,3S,4R,5R,6S)-4-hydroxy-6-methoxy-5-(sulfonatoamino)-2-((sulfonatooxy)methyl)tetrahydro-2H-pyran-3-yl)oxy)-5-(sulfonatooxy)tetrahydro-2H-pyran-3-yl)oxy)-5-(sulfonatoamino)-4-(sulfonatooxy)-2-((sulfonatooxy)methyl)tetrahydro-2H-pyran-3-yl)oxy)-3-(((2R,3R,4R,5S,6R)-4,5-dihydroxy-3-(sulfonatoamino)-6-((sulfonatooxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)-4,5-dihydroxytetrahydro-2H-pyran-2-carboxylate

(-20℃)

With Ice Pack

≥ 2 years